This analysis revealed similar odds of tumors with clinically actionable NSCLC molecular profiles between groups, notably for any EGFR mutation with adjustment for age, sex, and smoking status (p = 0.58). This evidence concerns the gene EGFR and non-small cell lung carcinoma.